Beech Hill Advisors, Inc. Amgen Inc Transaction History

Beech Hill Advisors, Inc.

$255 Million
Q3 2024

A detailed history of Beech Hill Advisors, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Beech Hill Advisors, Inc. holds 1,350 shares of AMGN stock, worth $354,577. This represents 0.17% of its overall portfolio holdings.

Number of Shares

1,350

Previous 2,150 37.21%

Holding current value

$354,577

Previous $671,000 35.32%

% of portfolio

0.17%

Previous 0.29%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 16, 2024	SELL	$309.38 - $337.38 $247,504 - $269,904	-800 Reduced 37.21%	1,350 $434,000
Q2 2023 Jul 10, 2023	SELL	$214.27 - $253.37 $26,783 - $31,671	-125 Reduced 5.49%	2,150 $477,000
Q1 2023 Apr 14, 2023	SELL	$225.79 - $275.2 $6,999 - $8,531	-31 Reduced 1.34%	2,275 $549,000
Q4 2022 Jan 17, 2023	SELL	$229.03 - $291.01 $50,157 - $63,731	-219 Reduced 8.67%	2,306 $0
Q2 2022 Jul 11, 2022	SELL	$230.71 - $256.74 $1,845 - $2,053	-8 Reduced 0.32%	2,525 $614,000
Q3 2021 Oct 14, 2021	BUY	$212.27 - $248.7 $1,698 - $1,989	8 Added 0.32%	2,533 $539,000
Q2 2021 Jul 15, 2021	BUY	$233.58 - $259.14 $93,432 - $103,656	400 Added 18.82%	2,525 $615,000
Q1 2021 Apr 19, 2021	SELL	$221.91 - $258.6 $12,870 - $14,998	-58 Reduced 2.66%	2,125 $529,000
Q4 2020 Jan 22, 2021	SELL	$216.38 - $257.67 $81,142 - $96,626	-375 Reduced 14.66%	2,183 $502,000
Q2 2019 Jul 15, 2019	BUY	$166.7 - $195.41 $50,010 - $58,623	300 Added 13.29%	2,558 $471,000
Q1 2018 Apr 23, 2018	BUY	$169.43 - $198.0 $43,204 - $50,490	255 Added 12.73%	2,258 $385,000
Q3 2017 Oct 20, 2017	BUY	$167.29 - $191.0 $335,081 - $382,573	2,003	2,003 $373,000

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $140B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Beech Hill Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Beech Hill Advisors, Inc. with notifications on news.

Account

Beech Hill Advisors, Inc. Amgen Inc Transaction History